We are live on ! Find out more
JAGX icon

Jaguar Health

7 hedge funds and large institutions have $283K invested in Jaguar Health in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% less ownership

Funds ownership: 0%0% (-0%)

22% less funds holding

Funds holding: 97 (-2)

27% less capital invested

Capital invested by funds: $387K → $283K (-$104K)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
1
Closed
4
Calls
Puts
Net Calls
Net Calls Change

JAGX Hedge Fund Activity: Q4 2024 in Review

7 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Jaguar Health (JAGX) for Q4 2024, worth a combined $283K — down 27% from $387K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of JAGX and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $35K. The largest seller was Goldman Sachs, exiting entirely with an estimated $59.5K sold.

  • 7 institutional investors held Jaguar Health (JAGX) as of Q4 2024, down from 9 in Q3 2024.
  • Funds reported $283K of Jaguar Health stock for Q4 2024, down 27% quarter-over-quarter.
  • 2 funds opened new Jaguar Health positions in Q4 2024 and 4 closed out, a net change of -2 holders.
  • The largest Jaguar Health buyer in Q4 2024 was HRT Financial, an estimated $35K added.
  • The largest Jaguar Health seller in Q4 2024 was Goldman Sachs, an estimated $59.5K sold.

Based on aggregated 13F filings for Q4 2024.